Cargando…
Opinion: PARP inhibitors in cancer—what do we still need to know?
PARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current consensus as to how PARPi work and how drug resistance to these agents emerges. We disc...
Autores principales: | Wicks, Andrew J., Krastev, Dragomir B., Pettitt, Stephen J., Tutt, Andrew N. J., Lord, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326299/ https://www.ncbi.nlm.nih.gov/pubmed/35892198 http://dx.doi.org/10.1098/rsob.220118 |
Ejemplares similares
-
Antimicrobial Mouthwashes: An Overview of Mechanisms—What Do We Still Need to Know?
por: Brookes, Zoë, et al.
Publicado: (2023) -
Secondary electron yield of surfaces: what we know and what we still need to know
por: Taborelli, M
Publicado: (2020) -
The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin
por: Krastev, Dragomir B., et al.
Publicado: (2022) -
Phytochemical Molluscicides and Schistosomiasis: What We Know and What We Still Need to Learn
por: Augusto, Ronaldo de Carvalho, et al.
Publicado: (2018) -
Biogenic Silver Nanoparticles: What We Know and What Do We Need to Know?
por: Rai, Mahendra, et al.
Publicado: (2021)